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Neuroendocrine neoplasms are considered to be 
composed of cells with features similar to those of the 
normal diffuse neuroendocrine system (DNES) scattered 
throughout the body (e.g. gastroenteropancreatic 
[GEP], the enteroendocrine hormonal signaling system; 
respiratory and urogenital systems; paraganglia; 
adrenal medulla; skin; thymus; heart; middle ear; 
and other tissues). Despite being considered rare, 
neuroendocrine neoplasm incidence has been reported 
to be increasing, with increased survival duration 
over time, suggesting that neuroendocrine tumors 
(NETs) are more prevalent than previously reported.1 
The present overview addresses the main focus on 
DNES cells and the anatomic pathology features of 
neuroendocrine neoplasms that occur in GEP.
The recognition of GEP DNES seems to have 
started in the 19th century. In 1870, Heidenhain2 
reported the presence of chromaffin cells (EC), a 
term later introduced by Ciaccio,3 in the gastric 
mucosa, probably the current gastric counterpart of 
the intestinal Enterochromaffin Cell: EC-Like (ECL) 
but it was Kultschitzky4 who reported a seminal 
study describing EC in Lieberkühn crypts of the 
intestinal mucosa. Then, Feyrter5 established the 
concept of a “diffuse” endocrine system (DNES) in 
the gastrointestinal mucosa. Neuroendocrine cells 
have been independently recognized by several 
authors and variably termed enterochromaffin 
cells, argentaffin and argyrophil “clear cells,” 
enteroendocrine cells, and Kultschitzky cells. Pearse6 
recognized that neuroendocrine cells of the gut uptake 
5-hydroxytryptophan, which is decarboxylated to 
5-hydroxytryptamine. Rosai,7 in a remarkable essay, 
presented claims favoring the endodermal origin 
of the GEP DNES, but pointed out that there was 
still evidence missing to definitively establish this 
possibility. The neuroendocrine cells express general 
markers of allegedly neuroendocrine differentiation 
(e.g. chromogranin and synaptophysin)—since a 
common phenotype does not mean a common 
histogenesis—and hormones according to site (e.g. 
a more “neural-like” differentiation in the larynx, 
lung, thymus, and thyroid; a more “epithelial-like” 
differentiation in the GEP system), and that an interplay 
seems to exist between these neuroendocrine cells and 
neural crest-derived nerve endings.
The first autopsy report of a GEP neuroendocrine 
neoplasm is ascribed to Langhans,8 which was followed 
by reports of Lubarsch9 and Ramson.10 Of note, it 
seems probable that the first description of a carcinoid 
tumor was reported in the bronchus by Laennec.11 
The term “carcinoid” was established (1907) by 
Oberndofer,12 who, in 1929,13 confirmed the possibility 
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that “karzinoide,” meaning “carcinoma-like,” might 
exhibit malignant features and metastasize.
Williams and Sandler14 reported three distinct 
groups of GEP neuroendocrine neoplasms: foregut 
(intrathoracic, gastric, and duodenal), midgut 
(small intestine, appendix, and proximal colon), and 
hindgut (distal colon and rectum). In 2000, the WHO 
(reviewed by Klöppel et al.15) established the following 
categories based on the degree of differentiation: 
well-differentiated endocrine tumors (further classified 
into benign tumors and low-grade malignant tumors, 
based on the tumor size, mitotic rate, Ki-67 labeling 
index, lymphovascular invasion, and symptoms, 
in association with hormonal oversecretion), and 
poorly differentiated endocrine (small- and large-cell) 
carcinomas. The WHO 201016 classification established 
GEP neuroendocrine (well-and poorly-differentiated) 
neoplasms as malignant tumors, except for gangliocytic 
paraganglioma and pancreatic neuroendocrine 
microadenomas, which are considered to be benign 
tumors; and L-cell–type (glucagon-like peptide and 
peptide YY-producing) NETs and tubular carcinoids, 
as uncertain malignancies.
Well-differentiated NETs are reported to occur 
most frequently in GEP sites up to two-thirds (more in 
the small intestine, but variably according to different 
reports), a quarter in the bronchopulmonary system, 
and the remaining 10% scattered throughout the 
body. In contrast, neuroendocrine carcinomas occur 
predominantly in the bronchopulmonary system.17
There are GEP neuroendocrine neoplasms 
associated with hereditary syndromes18 (e.g. multiple 
neuroendocrine neoplasia type 1 [MEN1], von 
Hippel-Lindau syndrome, neurofibromatosis 1, and 
tuberous sclerosis [TSC]), but most are considered 
sporadic. Well-differentiated sporadic pancreatic 
neuroendocrine neoplasms were reported to display a 
high frequency of mutations19 in MEN1, ATRX (alpha 
thalassemia/mental retardation syndrome X-linked), 
and DAXX (death-domain associated protein), 
which seem to associate with better behavior; and 
low frequency mutations in genes of the mTOR 
(mammalian target of rapamycin) pathways, such 
as PTEN (phosphatase and tensin homolog), TSC2, 
and PIC3CA (phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha). Interestingly, 
it seems that telomerase promoter mutations in 
pancreatic NETs are rare,20 but mainly found in tumors 
from patients with hereditary syndromes. Strikingly, 
most of the molecular mechanisms of neuroendocrine 
neoplasms remain to be clarified.
The current staging of GEP neuroendocrine 
neoplasms is  based on the proposals  of  the 
American Joint Committee on Cancer (AJCC)21 
and the European Neuroendocrine Tumor Society 
(ENETS).22,23 The AJCC and ENETS staging for almost 
all gastrointestinal neuroendocrine neoplasms—
those of the stomach, duodenum, ampulla, jejunum, 
ileum, and colon-rectum—are identical; whereas 
some differences exist in the T classification of 
the pancreatic and appendiceal neuroendocrine 
neoplasms between AJCC and ENETS staging.
GEP neuroendocrine neoplasms are graded22,23 
based on the mitotic count (MC)/10 high power 
fields (HPFs) and the Ki-67 proliferation index 
(Ki-67 LI), regardless of tumor size, extent, or location; 
a minimum of 50 HPFs (1 HPF = 2 mm2) should be 
carefully evaluated to accurately determine the MC, 
and 500–2000 cells to determine the percentage of 
KI-67 LI. GEP neuroendocrine neoplasms are usually 
graded as (well-differentiated) G1 (MC < 2/10HPF 
and/or ≤ 2% Ki-67LI) and G2 (MC 2-20/10 HPF and/or 
3-20% Ki-67 LI) NETs, and (poorly-differentiated, small 
or large cell) G3 neuroendocrine carcinomas (NECs; 
MC > 20/10HPF and/or > 20% Ki-67 LI). It is worth 
noting that there are reports24 of “well-differentiated 
G3 neuroendocrine neoplasms” that seem to display 
less aggressive behavior than bona fide NECs.
It  seems that up to 50% of NETs display 
synchronous or metacronous metastases after 
diagnosis (more common in poorly differentiated 
neoplasms), and appear to occur more frequently 
when the well-differentiated neuroendocrine primary 
neoplasm is located in the cecum or pancreas.25 Most 
metastases of neuroendocrine neoplasms occur in 
the liver, lungs, and bone, and are much rarer in 
other sites26 (e.g. brain, ear, ovary, breast, thyroid, 
pancreas, skin, adrenal glands, kidney, spleen, orbit, 
retroperitoneum, testis, and pituitary gland).
Conclusively, it seems that, as in the first medical 
identification of a GEP neuroendocrine neoplasm, 
autopsy studies are still very much justified27 to clarify 
the pathogenesis of cancer in general, and of NETs in 
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particular, especially in unusual cases and/or in cases 
submitted to the new medical therapies of cancer.
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